pp-264 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Renal disease
Clinical stage: Phase 3
Modality: Small molecule
Mechanism & Target: Antacid
Route & form: Oral
Differentiation: It is a non-absorbed polymer that binds hydrochloric acid (HCl) in the stomach, thereby increasing the serum bicarbonate concentration (SBC) without counterion exposure.
Manufacturer #39678
A late-stage clinical biopharmaceutical company focused on urology / nephrology. Developing a small molecule therapeutic targeting urology / nephrology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None